Semaglutide reduced a composite of CV events at 2 years in patients with type 2 diabetes and high CV risk
- PMID: 28114464
- DOI: 10.7326/ACPJC-2017-166-2-008
Semaglutide reduced a composite of CV events at 2 years in patients with type 2 diabetes and high CV risk
Comment on
-
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.N Engl J Med. 2016 Nov 10;375(19):1834-1844. doi: 10.1056/NEJMoa1607141. Epub 2016 Sep 15. N Engl J Med. 2016. PMID: 27633186 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical